Open AccessTargeting public neoantigens for cancer immunotherapy
Author(s) -
Alexander H. Pearlman,
Michael S. Hwang,
Maximilian F. Konig,
Emily HanChung Hsiue,
Jacqueline Douglass,
Sarah R. DiNapoli,
Brian J. Mog,
Chetan Bettegowda,
Drew M. Pardoll,
Sandra B. Gabelli,
Nicholas E. Papadopoulos,
Kenneth W. Kinzler,
Bert Vogelstein,
Shibin Zhou
Publication year - 2021
Publication title -
nature cancer
Language(s) - English
Resource type - Journals
ISSN - 2662-1347
DOI - 10.1038/s43018-021-00210-y
Subject(s) - immunotherapy , cancer immunotherapy , cancer , computational biology , medicine , identification (biology) , cancer research , antigen , immunology , biology , botany
Several current immunotherapy approaches target private neoantigens derived from mutations that are unique to individual patients' tumors. However, immunotherapeutic agents can also be developed against public neoantigens derived from recurrent mutations in cancer driver genes. The latter approaches target proteins that are indispensable for tumor growth, and each therapeutic agent can be applied to numerous patients. Here we review the opportunities and challenges involved in the identification of suitable public neoantigen targets and the development of therapeutic agents targeting them.